These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9655302)

  • 21. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy.
    Critz FA; Levinson AK; Williams WH; Holladay CT; Griffin VD; Holladay DA
    J Urol; 1999 Apr; 161(4):1199-203; discussion 1203-5. PubMed ID: 10081869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis.
    Horwitz EM; Levy LB; Thames HD; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Cancer; 2006 Oct; 107(7):1496-502. PubMed ID: 16944536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer.
    Williams SG; Duchesne GM; Millar JL; Pratt GR
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1082-7. PubMed ID: 15519778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
    Macdonald OK; D'Amico AV; Sadetsky N; Shrieve DC; Carroll PR
    Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
    Chautard D; Cellier P; Dalifard I; Pabot du Chatelard P; Chaussis F; Vielle B; Soret JY; Passagot J; Courte C; Daver A
    Prog Urol; 2002 Jun; 12(3):421-8. PubMed ID: 12189749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.
    Zagars GK; Pollack A; Kavadi VS; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):293-306. PubMed ID: 7538498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma.
    Potters L; Purrazzella R; Brustein S; Fearn P; Leibel SA; Kattan MW
    Cancer; 2002 Oct; 95(7):1451-6. PubMed ID: 12237913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
    deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
    Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
    D'Amico AV; Whittington R; Malkowicz SB; Cote K; Loffredo M; Schultz D; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
    Cancer; 2002 Jul; 95(2):281-6. PubMed ID: 12124827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy.
    Pinkawa M; Fischedick K; Piroth MD; Gagel B; Borchers H; Jakse G; Eble MJ
    Urology; 2007 Jan; 69(1):129-33. PubMed ID: 17270634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
    Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
    Satoh T; Ishiyama H; Matsumoto K; Tsumura H; Kitano M; Hayakawa K; Ebara S; Nasu Y; Kumon H; Kanazawa S; Miki K; Egawa S; Aoki M; Toya K; Yorozu A; Nagata H; Saito S; Baba S
    BJU Int; 2009 Apr; 103(8):1064-8. PubMed ID: 19040526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.
    Ludgate CM; Bishop DC; Pai H; Eldridge B; Lim J; Berthelet E; Blood P; Piercy GB; Steinhoff G
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1309-15. PubMed ID: 16029786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
    BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy.
    Gerber GS; Gornik HL; Goldfischer ER; Chodak GW; Rukstalis DB
    J Urol; 1998 Apr; 159(4):1243-6. PubMed ID: 9507845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer.
    D'Amico AV; Whittington R; Malkowicz SB; Schultz D
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):473-7. PubMed ID: 7538502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.